You searched for "presentation"
Treatment for cause of sudden sight loss now available through the NHS in England
The National Institute for Health and Care Excellence (NICE) has approved a treatment for Leber Hereditary Optic Neuropathy (LHON), called Idebenone (Raxone), in those aged 12 and above who are affected by the condition. LHON is a rare mitochondrial genetic...OXSIGHT Onyx – A sight-enhancing wearable
The Onyx is a newly-released (late 2021) wearable with a powered magnifier to assist those with central vision impairment. Unlike the previously covered wearable devices, this enhances existing sight. The unit can either be held against the eyes when needed,...Use of off-the-shelf magnifying glasses as a cost-effective alternative for surgical loupes
Surgical loupes are an integral part of ophthalmic surgery on the ocular surface and in the periocular area. Available in different magnifications, they provide a clear view of the field of surgery which can greatly assist in identifying fine structures...
How many injections in nAMD: ranibizumab vs. aflibercept
Intravitreal anti-VEGF injections make up a large proportion of the workload in ophthalmology clinics. Since the introduction of aflibercept with eight weekly injections there has been an option to use a treatment which may require less treatment, with potential cost...
Is an increased homocysteine level associated with greater risk of AMD?
Basic research studies have implicated homocysteine in causing vascular endothelial dysfunction and inflammation, and this has been borne out in large observational studies which suggested that elevated homocysteine is associated with increased risk of cardiovascular disease. In order to determine...
Ranibizumab for the treatment of age-related macular degeneration
This multicentre randomised prospective open label study compared 0.5 versus 2mg of ranibizumab in patients with submacular retinal pigment epithelial (RPE) detachment due to age-related macular degeneration. Four treatment regimens were used for the two strengths either monthly for 12...
Detection of antiranibizumab antibodies in exudative AMD
In this study the authors aimed to detect immune response to ranibizumab treatment in wet age-related macular degeneration (AMD). An ELISA was employed to quantify the anti-ranibizumab titre which was compared against the control anti-abciximab titre. Titres of anti-ranibizumab antibodies...
Role of fundus autofluorescence patterns and baseline atrophy area on geographic atrophy progression
Central geographic atrophy (GA) is one of the morphological sub types of late-stage macular degeneration. The natural course of the disease is characterised by expanding areas of macular atrophy, which cause absolute scotoma. Fundus autofluorescence (FAF) is derived from lipofuscin...
Visual acuity after cataract surgery in AMD patients
The data from this study are obtained from the Age-Related Eye Disease Study (AREDS) 2 and analysed to evaluate if cataract surgery benefits patients with concurrent age-related macular degeneration (AMD). The AREDS 2 was a five year, prospective, multi-centre randomised...
Reduced blood flow and age-related macular degeneration
This was a prospective cross-sectional study assessing changes in blood flow velocity in patients with age-related macular degeneration (AMD) using a retinal function imager. Sixty eyes with wet AMD were compared to 53 control eyes and the average blood flow...
Oral proton pump inhibitors in macular degeneration patients
The authors report five patients with advanced wet macular degeneration and poor vision with onset or enhancement of visual hallucinations with the use of proton pump inhibitors for heartburn management. The hallucinations were reversible with discontinuation of medication. The authors...
